Advertisment
Indian Journal of Nephrology About us |  Subscription |  e-Alerts  | Feedback | Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Current Issue | Archives| Ahead of print | Search |Instructions |  Editorial Board  

Users Online:67

Official publication of the Indian Society of Nephrology
  Search
 
  
 ~  Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~Related articles
 ~  Article in PDF (590 KB)
 ~  Citation Manager
 ~  Access Statistics
 ~  Reader Comments
 ~  Email Alert *
 ~  Add to My List *
* Registration required (free)  

 
   Abstract
  Background
  Methods
  Results
  Discussion
  Conclusion
   References
   Article Tables

 Article Access Statistics
    Viewed1149    
    Printed98    
    Emailed0    
    PDF Downloaded192    
    Comments [Add]    

Recommend this journal

 


 
  Table of Contents  
ORIGINAL ARTICLE
Year : 2020  |  Volume : 30  |  Issue : 2  |  Page : 72-76
 

Vitamin D receptor activity, vitamin D status, and development of de-novo donor-specific antibody after renal transplantation


Department of Nephrology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Rae Bareli Road, Lucknow, Uttar Pradesh, India

Date of Submission09-Nov-2018
Date of Acceptance15-Feb-2019
Date of Web Publication07-Feb-2020

Correspondence Address:
Raj K Sharma
Department of Nephrology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow - 226 014, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijn.IJN_353_18

Rights and Permissions

  Abstract 


Introduction: Vitamin D has immunomodulatory properties and could have a role in allograft outcome. Methods: Fifty-two chronic kidney disease patients going for transplantation were studied for vitamin-D receptor (VDR) activity, 25(OH)D, estimated glomerular filtration rate (e-GFR), and de-novo donor-specific antibody (d-DSA). Results: Vitamin D deficiency was seen in 25% of recipients before transplant (26.09 ± 12.19 ng/ml), in 48.1% at 6 months posttransplant (23.36 ± 15.11 ng/ml). VDR activity before the transplant was 15.41 ± 31.41 ng/ml, which was similar to control group (13.24 ± 9.78 ng/ml), and after transplantation showed an increase at 3 months to 21.91 ± 38.80 ng/ml and at 6 months to 26.03 ± 53.90 ng/ml. d-DSA developed in 27.3% and 6.7% patients of vitamin D-deficient patients (levels <31 ng/ml) and non-deficient (levels ≥20 ng/ml) patients respectively (P < 0.042). Low VDR activity at 3 months posttransplant was associated with significantly higher d-DSA positivity (33.3%) as compared to the group with normal VDR activity where d-DSA developed only in 5.9% of patients (P < 0.009). Patients with vitamin D levels <20 ng/ml and the group with low VDR activity at 3 months had significantly less e-GFR at 1 year after transplant. Conclusion: d-DSA was associated with vitamin D deficiency and low VDR activity with decreased graft GFR at 12 months posttransplant.


Keywords: De-novo DSA, estimated GFR, kidney transplantation, VDR activity, vitamin D deficiency


How to cite this article:
Mehrotra S, Sharma RK, Mayya M. Vitamin D receptor activity, vitamin D status, and development of de-novo donor-specific antibody after renal transplantation. Indian J Nephrol 2020;30:72-6

How to cite this URL:
Mehrotra S, Sharma RK, Mayya M. Vitamin D receptor activity, vitamin D status, and development of de-novo donor-specific antibody after renal transplantation. Indian J Nephrol [serial online] 2020 [cited 2020 Nov 26];30:72-6. Available from: https://www.indianjnephrol.org/text.asp?2020/30/2/72/277940





  Background Top


Observational studies have demonstrated that vitamin D deficiency, defined as low serum total 25-hydroxyvitamin-d concentration, is associated with increased risks of death and diseases such as cardiovascular diseases, malignancies, infectious diseases, diabetes, autoimmune diseases, and kidney diseases.[1],[2] The prevalence of vitamin D deficiency or insufficiency is high among patients with chronic kidney disease (CKD), especially patients with end-stage renal disease (ESRD) and kidney transplant recipients.[3],[4] The vitamin D receptor (VDR) is a nuclear protein responsible for mediating the biological actions of vitamin D.[5]

Vitamin D deficiency has been defined as 25(OH)D concentration <31 ng/ml, and insufficiency as 25(OH)D concentration between ≥20 and <31 ng/ml. As defined in KDIGO guidelines, about 97% of patients in CKD stage 5 have vitamin D deficiency or insufficiency.[6] In renal transplantation, vitamin D could have an additional role in immune modulation. VDRs are present on various immune cells, including T cells, B cells, monocytes, and antigen-presenting cells.[7],[8] In T cells, calcitriol suppresses helper T-cell proliferation and differentiation, alters cytokine production, and causes a shift from a proinflammatory Th1 response to a tolerogenic Th2 response.[9],[10],[11] Calcitriol also inhibits dendritic cell (DC) differentiation and maturation into antigen-presenting cells, which may be protective in transplantation.[12] In a rat model of chronic allograft nephropathy, administration of 1,25 dihydroxyvitamin-D prolonged allograft survival, decreased episodes of acute rejection, reduced proteinuria, and prevented histological changes associated with chronic allograft nephropathy.[13] This suggests that vitamin D supplementation may reduce acute rejection and chronic allograft nephropathy in humans through its interactions with the immune system.


  Methods Top


Fifty-two CKD patients on dialysis going for transplantation were prospectively studied before and after renal transplantation. VDR activity, 25(OH)D, and estimated glomerular filtration rate (e-GFR) were evaluated and correlated with the development of de-novo donor-specific antibody (d-DSA). VDR activity was measured in serum by human vitamin D3 receptor (VDR) ELISA kit (http://www.eiaab.com/entries/f_vitamin%20dCatalog No: E0475h). 25(OH)D (http://www.laboratoireduquaivalliere.fr/notices%20analyses/FicheTechniqueVITD.pdf) in serum was estimated by chemiluminescence microparticle immunoassay (Architect i-1000 STAT ABBOTT).

HLA typing was done on Luminex platform using Thermo-fisher kits. d-DSA was evaluated by two different solid phase assays by Luminex technology, using donor lysate DSA assay (Immucor), and single antigen bead assay (Thermo-fisher).[14] d-DSA was considered positive with Mean Fluorescence Intensity (MFI) of 1000 or above. e-GFR was measured using the CKD-Epidemiology Collaboration (CKD-EPI) equation, which confers less underestimation of GFR in subjects with normal renal function. As there is no consensus regarding normal VDR activity parameters in transplant recipients. We used 25th percentile of normal control as cutoff for lower limit to define normal levels of VDR receptor activity.[15]

Statistical analysis

Data was expressed as mean values ± standard deviation and as absolute and relative frequency for categorical variables. Statistical analysis was performed using SPSS software (Version 20.0). Graft function at 3 months, 6 months, and 1 year was compared between the groups by analysis of covariance, taking into account covariates like e-GFR value at 1 year and 25-hydroxyvitamin D3 at baseline, at 3 months and 6 months. Various categorical variables were analyzed using Pearson's correlation, Chi-square test, and Fisher's exact test. Multiple linear regression statistics was used with e-GFR as dependent variable and other factors as independent variables. Other statistical tests as appropriate were applied to various factors and variables.


  Results Top


Fifty-two CKD (82.7% male) patients on dialysis going for transplantation were prospectively studied before and after renal transplantation. Patient characteristics and demographic data are given in [Table 1]. Various parameters like VDR activity, 25(OH)D levels and e-GFR were analysed in pre and post transplant period. 25(OH)D and VDR status were correlated with the development of d-DSA at 3 months of transplantation. Patients were evaluated at 3, 6, and 12 months intervals. 25(OH)D levels indicated vitamin D deficiency in 25% of patients before transplant (26.09 ± 12.19 ng/ml). In posttransplant period, vitamin D deficiency was seen at 3 months in 43.1% (23.44 ± 10.64 ng/ml), whereas at 6 months, in 48.1% (23.36 ± 15.11 ng/ml). VDR activity before transplant (15.41 ± 31.41 ng/ml), was similar to control group (13.24 ± 19.30 ng/ml). After transplantation, VDR activity showed an increase to 21.91 ± 38.80 ng/ml at 3 months and further increased at 6 months to 26.03 ± 53.90 ng/ml (P value <31.010 as compared to control). Comparison between groups with e-GFR <31 and ≥60 ml/min/1.73 m2 showed that posttransplant GFR at 12 months correlated positively with pretransplant VDR activity at baseline (P = 0.005), at 3 months (P value = 0.035), and VDR activity at 6 months (P = 0.043) posttransplant [Table 2]. d-DSA developed more significantly in patients with vitamin D deficiency (30.7%) as compared to patients without vitamin D deficiency (5.5%) (Chi-square test, P < 0.042) (Pearson's correlation P = 0.043).
Table 1: Patient demographics

Click here to view
Table 2: Descriptive statistics of vitamin D (pre- and post-kidney transplant) compared with graft e-GFR category at 12 months (post-KT)

Click here to view


Low VDR activity at 3 months posttransplant was associated with significantly higher d-DSA positivity (33.3%) as compared to the group with normal VDR activity where d-DSA developed only in 5.9% (P < 0.009, Pearson's correlation P = 0.008) [Table 3]. In our study, DSA positivity was associated with increased rejection episodes (25%) as compared to d-DSA negative (6.8% rejections). All the patients except one were on tacrolimus-based immunosuppression. Tacrolimus levels at 1 month were 13.47 ± 6.06 ng/ml (normal target range of 10–15 ng/ml at 1 month).
Table 3: Correlation between 25(OH)D levels, VDR activity, and d-DSA at 3-month posttransplant

Click here to view


Multivariate analysis revealed that 2 weeks post transplant GFR, 3 months VDR, and 6 months VDR (considered as continuous variables) were independent predictors of 12-month GFR of allograft [Table 4].
Table 4: Model summary of multivariate linear regression analysis

Click here to view



  Discussion Top


Our study shows that there is a high prevalence of vitamin D deficiency and insufficiency in patients with ESRD going for transplantation and it persists even after kidney transplantation in majority of patients as compared to control population.[16] This is also supported by our results, which show that pretransplant VDR activity was low. After the transplant, VDR activity became normal at 3 months. VDR activity was higher as compared to the control group at 6 months posttransplant. In our study, we used vitamin D supplements only in pretransplant period. No vitamin D analog was used in the posttransplant period. Transplant patients had low 25(OH)D. Patients after transplant though achieved good graft function (as indicated by serum creatinine levels), but the e-GFR was still suboptimal in posttransplant period.

Vitamin D deficiency has been reported to be associated with risk of acute rejections in posttransplant period. Vitamin D as an immunomodulator has potential for reducing and preventing allograft rejection after transplantation.[17],[18],[19] At 3 months posttransplant, development of d-DSA in our patients was significantly associated with vitamin D deficiency (P < 0.042) and low VDR activity (P < 0.009). Vitamin D has been shown to control both innate and adaptive immune responses[20],[21] and could modulate allogeneic response. Our results indicate that lower levels of 25(OH)D and low VDR activity are linked to development of d-DSA. This effect of vitamin D deficiency on development of d-DSA could adversely affect allograft function, consequence of the associated stronger alloimmune response.[22] Prevalence of 25(OH)D deficiency at the time of renal transplantation has been reported to be quite high.[23]

We correlated d-DSA development with vitamin D status after transplantation. Studies in CYP27B1 knockout mice suggest that VDR activity correlates with number of mature DCs and is associated with aberrant DC trafficking.[9] VDR expression in human B cells may be upregulated by activated B cells. In vitro studies show that B cells are capable of intracrine response to bioactive metabolite of vitamin D. The antiproliferative effects of 1,25(OH)2D3 (i.e., stimulation of apoptosis, suppression of proliferation and differentiation, decreased production of immunoglobulin) on B cells have been reported to be indirectly driven by T-helper cells.[24] In our study, development of d-DSA was associated with low VDR activity at 3 months after transplantation (33.3% d-DSA positivity in low VDR activity group and 5.9% d-DSA positivity in group with normal VDR activity, P < 0.009). Despite normal levels of 1,25-(OH)2D, the insufficient expression of VDR has been reported to be responsible for an impaired translation of vitamin D-induced signaling, which can contribute to a sustained inflammatory reaction.[25]

VDR activity can modulate immune response. VDR activity has been reported to affect and inhibit progression of CKD in animal models of nonimmunological CKD diseases. VDR activity also helps to preserve podocyte function.[26] VDR activity and signaling reduces glomerular inflammation and tubular cell proliferation and interferes with the renin–angiotensin system, epidermal growth factor receptor activity, and transforming growth factor (TGF)-β signaling.[16],[27],[28]

In our study, VDR, gender, immunosuppression, tacrolimus levels, proteinuria, rejection, and induction were studied by binary and linear logistic regression models. Low GFR correlated negatively with induction and VDR receptor activity. On backward selection (binary logistic regression), only induction with basiliximab or thymoglobulin showed significant correlation, whereas in linear regression model, 3- and 6-month VDR activity was predictor of graft GFR. Other parameters studied did not predict GFR at 1 year posttransplant. In our study, all patients except one were on tacrolimus-based triple immunosuppression. No patient was on steroid-free immunosuppression [Table 1].

Low 25(OH) vitamin D levels have been reported to be associated with poorer graft function and faster GFR decline. There is no report about vitamin D levels and DSA.[16],[29] Low 25(OH) vitamin D levels have been reported to be associated with inferior kidney function on the long term.[30] Vitamin D supplementation in randomized controlled (RCT) and retrospective trials has not shown renoprotective effects.[31],[32] While supplementation with paricalcitol has been shown to reduce proteinuria as renoprotective mechanism, paricalcitol has been reported to be a VDR activator in animal models.[33]

It is possible that VDR activation may be more effectively mediated by paricalcitol than by 25(OH) vitamin D. This may explain the result of RCTs of vitamin D supplementation. These RCTs have also not looked at VDR activity and DSA.

In the present study, VDR levels and induction have been shown to be significant predictors of graft function. The main new finding of this study is that better VDR activity is associated with better graft function.


  Conclusion Top


In the present study, vitamin D deficiency and low VDR activity was associated with the d-DSA development and decreased graft e-GFR at 12 months posttransplant. Future studies are required to test whether vitamin D supplementation after kidney transplantation could improve allograft outcomes.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Weinstock MA, Moses AM. Skin cancer meets vitamin D: The way forward for dermatology and public health. J Am Acad Dermatol 2009;61:720-4.  Back to cited text no. 1
    
2.
Christie FT, Mason L. Knowledge, attitude and practice regarding vitamin D deficiency among female students in Saudi Arabia: A qualitative exploration. Int J Rheum Dis 2011;14:e22-9.  Back to cited text no. 2
    
3.
González EA, Sachdeva A, Oliver DA, and Martin KJ, Vitamin D insufficiency and deficiency in chronic kidney disease: A single center observational study, Am J Nephrol 2004;24:503-10.  Back to cited text no. 3
    
4.
Stavroulopoulos A, Cassidy MJD, Porter CJ, Hosking DJ, Roe SD, Vitamin D statusin renal transplant recipients, Am J Transplant 2007;7:2546-52.  Back to cited text no. 4
    
5.
Strugnell SA, DeLuca HF. The vitamin D receptor-structure and transcriptional activation. Proc Soc Exp Biol Med 1997;215:223.  Back to cited text no. 5
    
6.
National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(Suppl 3):S1-201.  Back to cited text no. 6
    
7.
Prietl B, Treiber G, Pieber TR, Amrein K. Vitamin D and immune function. Nutrients 2013;5:2502-21.  Back to cited text no. 7
    
8.
Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: Vitamins A and D take centre stage. Nat Rev Immunol 2008;8:685-98.  Back to cited text no. 8
    
9.
Hewison M. An update on vitamin D and human immunity. Clin Endocrinol 2012;76:315-25.  Back to cited text no. 9
    
10.
Di Rosa M, Malaguarnera M, Nicoletti F, Malaguarnera L. Vitamin D3: A helpful immuno-modulator. Immunology 2011;134:123-39.  Back to cited text no. 10
    
11.
Van Belle TL, Gysemans C, Mathieu C. Vitamin D in autoimmune, infectious and allergic diseases: A vital player? Best Pract Res Clin Endocrinol Metab 2011;25:617-32.  Back to cited text no. 11
    
12.
Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A. 1α,25-dihydroxyvitamin d3 has a direct effect on naive CD4+ T cells to enhance the development of Th2 cells. J Immunol 2001;167:4974-80.  Back to cited text no. 12
    
13.
Hullett DA, Laeseke PF, Malin G, Nessel R, Sollinger HW, Becker BN. Prevention of chronic allograft nephropathy with vitamin D. Transpl Int 2005;18:1175-86.  Back to cited text no. 13
    
14.
Mehrotra S, Sharma RK, Mayya M, Gupta A, Prasad N, Kaul A, et al. Luminex solid-phase crossmatch for de novo donor-specific antibodies in living-donor related transplants. Exp Clin Transplant 2017;4:394-9.  Back to cited text no. 14
    
15.
Pablo UT, Marie M, Jean PH, Alexandre K, Jean JB, Martin F, et al. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. Am J Kidney Dis 2011;58:544-53.  Back to cited text no. 15
    
16.
Bienaimé F, Girard D, Anglicheau D, Canaud G, Souberbielle JC, Kreis H, et al. Vitamin D status and outcomes after renal transplantation. J Am Soc Nephrol 2013;24:831-41.  Back to cited text no. 16
    
17.
Saber A, Fotuhi F, Rostami Z, Einollahi B, Nemati E. Vitamin D levels after kidney transplantation and the risk of cytomegalovirus infection. Nephrourol Mon 2015;7:e29677.  Back to cited text no. 17
    
18.
Park YJ, Kim SU, Lee KH, Lee JH, Kwon E, Jung HY, et al. Vitamin D deficiency is associated with increased risk of bacterial infections after kidney transplantation. Korean J Intern Med 2017;32:505-13.  Back to cited text no. 18
    
19.
Stein EM, Shane E. Vitamin D in organ transplantation. Osteoporos Int 2011;22:2107-18.  Back to cited text no. 19
    
20.
Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: Modulator of the immune system. Curr Opin Pharmacol 2010;10:482-96.  Back to cited text no. 20
    
21.
Hewison M. Vitamin D and innate and adaptive immunity. Vitam Horm 2011;86:23-62.  Back to cited text no. 21
    
22.
Filipov JJ, Zlatkov BK, Dimitrov EP, Svinarov D. Relationship between vitamin D status and immunosuppressive therapy in kidney transplant recipients. Biotechnol Biotechnol Equip 2015;4;29:331-5.  Back to cited text no. 22
    
23.
Sadlier DM, Magee CC. Prevalence of 25(OH) vitamin D (calcidiol) deficiency at time of renal transplantation: A prospective study. Clin Transplant 2007;21:683-8.  Back to cited text no. 23
    
24.
Lemire JM, Adams JS, Sakai R, Jordan SC. 1 alpha, 25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest 1984;74:657-61.  Back to cited text no. 24
    
25.
Kempinska-Podhorodecka A, Milkiewicz M, Wasik U, Ligocka J, Zawadzki M, Krawczyk M. Decreased expression of vitamin D receptor affects an immune response in primary biliary cholangitis via the VDR-miRNA155-SOCS1 Pathway. Int J Mol Sci 2017;18:E289. doi: 10.3390/ijms18020289.  Back to cited text no. 25
    
26.
Li YC. Podocytes as target of vitamin D. Curr Diabetes Rev 2011;7:35-40.  Back to cited text no. 26
    
27.
Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110:229-38.  Back to cited text no. 27
    
28.
Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, Slatopolsky E. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007;18:1796-806.  Back to cited text no. 28
    
29.
Keyzer CA, Riphagen IJ, Joosten MM, Navis G, Muller Kobold AC, Kema IP, et al.; NIGRAM consortium. Associations of 25(OH) and 1,25(OH)2 vitamin D with long-term outcomes in stable renal transplant recipients. J Clin Endocrinol Metab 2015;100:81-9.  Back to cited text no. 29
    
30.
Obi Y, Hamano T, Ichimaru N, Tomida K, Matsui I, Fujii N, et al. Vitamin D deficiency predicts decline in kidney allograft function: A prospective cohort study. J Clin Endocrinol Metab 2014;99:527-35.  Back to cited text no. 30
    
31.
Courbebaisse M, Souberbielle JC, Baptiste A, Taieb J, Tsatsaris V, Guibourdenche J, et al. Cholecalciferol supplementation does not protect against renal allograft structural and functional deterioration: A retrospective study. Transplantation 2011;91:207-12.  Back to cited text no. 31
    
32.
Thiem U. VITA-D study: Outcome of a 1-year randomized controlled trial transplant patients. European Renal Association- European Dialysis and Transplant Association (ERA-EDTA) 52nd Congress: Abstract LBA-3564, London, UK, 28-31 May, 2015.  Back to cited text no. 32
    
33.
Park JW, Bae EH, Kim IJ, Ma SK, Choi C, Lee J, et al. Paricalcitol attenuates cyclosporine-induced kidney injury in rats. Kidney Int 2010;77:1076-85.  Back to cited text no. 33
    



 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4]



 

Top
Print this article  Email this article
 

    

Indian Journal of Nephrology
Published by Wolters Kluwer - Medknow
Online since 20th Sept '07